CD19 and glioblastoma: Tandem CAR-T has been developed to target HER-2 and IL13Rα2 in solid tumors [105], bispecific CD19/CD20 has been designed for B cell malignancies [106], and, more recently, a trivalent CAR T-cell construct has been developed for glioblastoma [107].